Absci is trading 10.40% higher at $9.87, rebounding after three consecutive declining closes; no fresh company-specific catalyst for the October 9 move was found. - XBI is up 2.50%, alongside two biotech IPO debuts; this sector strength may support the move, but coverage does not directly link it to Absci’s gain. - Recent company coverage concerns previously outlined trial plans, not a new announcement.